for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Catalyst Pharmaceuticals Inc

CPRX.OQ

Latest Trade

5.08USD

Change

0.03(+0.59%)

Volume

347,730

Today's Range

4.96

 - 

5.15

52 Week Range

2.88

 - 

6.23

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.05
Open
5.02
Volume
347,730
3M AVG Volume
16.58
Today's High
5.15
Today's Low
4.96
52 Week High
6.23
52 Week Low
2.88
Shares Out (MIL)
102.98
Market Cap (MIL)
523.13
Forward P/E
12.88
Dividend (Yield %)
--

Next Event

Catalyst Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual)

Latest Developments

More

Catalyst Pharmaceuticals Posts Q1 EPS Of $0.07

Catalyst Pharmaceuticals Announces $40 Mln Share Repurchase Program

Catalyst Pharmaceuticals Posts Q4 EPS Of $0.11

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company. The Company is focused on in-licensing, developing, and commercializing medicines for patients living with rare diseases. The Company is developing a pipeline of medicines for other rare diseases. The Company's product Firdapse Tablet, 10 mg, is used for the treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS) patients (ages 17 and above) in the United States and Canada. Firdapse consists of the phosphate salt of amifampridine. It is developing a long-acting formulation of amifampridine phosphate. The Company's Firdapse is also developing clinical trials for the treatment of muscle-specific receptor tyrosine kinase-positive myasthenia gravis (MuSK-MG). Catalyst Pharmaceuticals Ireland, Ltd. is the subsidiary of the Company.

Industry

Biotechnology & Drugs

Contact Info

355 ALHAMBRA CIRCLE, SUITE 801

CORAL GABLES, FL

33134

United States

+1.305.5292522

https://catalystpharma.com/

Executive Leadership

Patrick James McEnany

Chairman of the Board, President, Chief Executive Officer

Alicia Grande

Chief Financial Officer, Vice President, Treasurer

Steven R. Miller

Chief Operating Officer, Chief Scientific Officer

Brian D. Elsbernd

Chief Compliance Officer, Chief Legal Officer

Mary Coleman

Vice President, Head of Investor Relations

Key Stats

2.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.1K

2020

0.1K

2021(E)

0.1K
EPS (USD)

2018

-0.330

2019

0.300

2020

0.710

2021(E)

0.392
Price To Earnings (TTM)
7.25
Price To Sales (TTM)
4.12
Price To Book (MRQ)
2.77
Price To Cash Flow (TTM)
6.99
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
49.06
Return on Equity (TTM)
43.82

Latest News

Latest News

BRIEF-Catalyst Pharma Sees FY 2020 Revenue $135 Mln To $155 Mln

* DRUG SUPPLY REMAINS WELL-STOCKED WITH PATIENTS HAVING ACCESS TO UNINTERRUPTED SUPPLY OF FIRDAPSE (AMIFAMPRIDINE) 10MG

BRIEF-Catalyst Pharmaceuticals CEO, On Impact Of Covid-19, Says Implementing Virtual Approach To Guarantee Patients Continual Access To Firdapse

* CATALYST PHARMACEUTICALS CEO, ON IMPACT OF COVID-19, SAYS IMPLEMENTING VIRTUAL APPROACH TO GUARANTEE PATIENTS CONTINUAL ACCESS TO FIRDAPSE

BRIEF-Catalyst Pharmaceuticals Reports Q4 GAAP Earnings Per Share $0.07

* CATALYST PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR-END 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Catalyst Pharma sues FDA over approval of cheaper rival drug

Catalyst Pharmaceuticals Inc, which has come under fire for the high price tag on its rare disease drug, on Wednesday sued the U.S. Food and Drug Administration to challenge the recent approval of a lower-cost rival drug.

Catalyst Pharma files lawsuit against U.S. FDA on Jacobus Pharma drug approval

Catalyst Pharmaceuticals Inc said on Wednesday it has filed a lawsuit against the U.S. Food and Drug Administration, challenging the recent approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for a rare neuromuscular disease.

U.S. Senator Sanders urges FDA to allow older versions of $375,000 drug

U.S. Senator Bernie Sanders this week urged regulators to allow pharmacies and manufacturers to resume distributing unbranded, lower-cost versions of a drug used to treat a rare neuromuscular disorder, according to a letter provided by his office to Reuters.

Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke

Catalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its high drug prices, on Thursday defended its $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry.

Catalyst defends drug price after Bernie Sanders' rebuke

Catalyst Pharmaceuticals Inc, targeted by U.S. Senator Bernie Sanders for high drug prices, said on Thursday that prices of its treatment for a rare neurological disorder were "in line" with similar products in the industry.

Catalyst Pharma sees net price of drug, once free, topping $300,000

Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.

U.S. FDA approves Catalyst Pharma's rare disease drug

The U.S. Food and Drug Administration approved on Wednesday Catalyst Pharmaceuticals Inc's drug to treat a rare autoimmune disease.

U.S. FDA approves Catalyst Pharma's rare disease drug

The U.S. Food and Drug Administration approved on Wednesday Catalyst Pharmaceuticals Inc's drug to treat a rare autoimmune disease.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up